Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Galie, D. Richards, T. Hutchinson, C. Dufton, On Behalf of the ARIES Study Group (Bologna, Italy; Harlow, Essex, United Kingdom; Westminster, CO, United States Of America). Ambrisentan therapy for patients with PAH associated with connective tissue disease (PAH-CTD): one year follow-up. Eur Respir J 2008; 32: Suppl. 52, 1418

Member's Comments

No comment yet.

Related content which might interest you: One year follow-up of patients with idiopathic pulmonary fibrosis treated with immunosuppressive therapy Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases Year: 2007 Choosing pharmacotherapy for ILD in patients with connective tissue disease Source: Breathe, 17 (4) 210114; 10.1183/20734735.0114-2021 Year: 2021 Double combination therapy in patients with pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 An observational study on effectiveness of azathioprine in treatment of interstitial lung disease secondary to connective tissue disease Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Systemic inflammatory response during one year follow-up in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004 The effectiveness of plasmaferesis in patients with relapsing and progressing course of pulmonary sarcoidosis (5 years follow-up) Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 Ambrisentan therapy for PAH patients with WHO class II symptoms: one year follow-up. Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Intravenous cyclophosphamide therapy for patients with interstitial pulmonary disease associated with collagen vascular disorders. A single-center experience Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Does lung function predict response to therapy in PAH associated with connective tissue disease? Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology Year: 2012 Sitaxsentan improves 6MW and hemodynamics in patients with pulmonary arterial hypertension (PAH) related to connective tissue disease (CTD) Source: Eur Respir J 2005; 26: Suppl. 49, 564s Year: 2005 Four year experience of a dedicated connective tissue disorder pulmonary hypertension clinic Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009 5 year survival of patients with distal chronic thromoembolic pulmonary hypertension; comparison of treated patients with distal disease and residual disease post pulmonary endartectomy Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Efficacy of rituximab in patients with connective tissue disease associated interstitial lung disease: Preliminary results in safety and clinical response Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Infliximab therapy in patients with chronic progressive sarcoidosis – a retrospective follow-up study Source: Annual Congress 2008 - Sarcoidosis: pathophysiology and severity Year: 2008 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 One year follow-up on pulmonary function for lobectomized patients. Source: International Congress 2017 – General thoracic surgery Year: 2017 Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD) Source: International Congress 2015 – Connective tissue disorders Year: 2015